These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 38820163

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Bacteriophages as potential antibiotic potentiators in cystic fibrosis: A new model to study the combination of antibiotics with a bacteriophage cocktail targeting dual species biofilms of Staphylococcus aureus and Pseudomonas aeruginosa.
    Wang Z, De Soir S, Glorieux A, Merabishvili M, Knoop C, De Vos D, Pirnay JP, Van Bambeke F.
    Int J Antimicrob Agents; 2024 Sep; 64(3):107276. PubMed ID: 39009289
    [Abstract] [Full Text] [Related]

  • 5. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.
    Koeva M, Gutu AD, Hebert W, Wager JD, Yonker LM, O'Toole GA, Ausubel FM, Moskowitz SM, Joseph-McCarthy D.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923873
    [Abstract] [Full Text] [Related]

  • 6. Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.
    Howlin RP, Cathie K, Hall-Stoodley L, Cornelius V, Duignan C, Allan RN, Fernandez BO, Barraud N, Bruce KD, Jefferies J, Kelso M, Kjelleberg S, Rice SA, Rogers GB, Pink S, Smith C, Sukhtankar PS, Salib R, Legg J, Carroll M, Daniels T, Feelisch M, Stoodley P, Clarke SC, Connett G, Faust SN, Webb JS.
    Mol Ther; 2017 Sep 06; 25(9):2104-2116. PubMed ID: 28750737
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice.
    Kirby BD, Al Ahmar R, Withers TR, Valentine ME, Valentovic M, Long TE, Gaskins JR, Yu HD.
    Antimicrob Agents Chemother; 2019 Jul 06; 63(7):. PubMed ID: 31010865
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Organic Acids and Their Salts Potentiate the Activity of Selected Antibiotics against Pseudomonas aeruginosa Biofilms Grown in a Synthetic Cystic Fibrosis Sputum Medium.
    Bao X, Bové M, Coenye T.
    Antimicrob Agents Chemother; 2022 Jan 18; 66(1):e0187521. PubMed ID: 34807756
    [Abstract] [Full Text] [Related]

  • 10. Activity of Antibiotics against Pseudomonas aeruginosa in an In Vitro Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium.
    Diaz Iglesias Y, Van Bambeke F.
    Antimicrob Agents Chemother; 2020 Mar 24; 64(4):. PubMed ID: 32015047
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Anti-Persisters Activity of Lacticaseibacillus rhamnosus Culture Filtrates against Pseudomonas aeruginosa in Artificial Sputum Medium.
    Bianchi M, Esin S, Kaya E, Batoni G, Maisetta G.
    Int J Mol Sci; 2024 Jun 28; 25(13):. PubMed ID: 39000222
    [Abstract] [Full Text] [Related]

  • 13. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M, Morosini MI, Köksal E, Oliver A, Ekkelenkamp M, Cantón R.
    Antimicrob Agents Chemother; 2018 Jan 28; 62(1):. PubMed ID: 29084746
    [Abstract] [Full Text] [Related]

  • 14. Pf bacteriophage is associated with decline in lung function in a longitudinal cohort of patients with cystic fibrosis and Pseudomonas airway infection.
    Burgener EB, Gupta A, Nakano K, Gibbs SL, Sommers ME, Khosravi A, Bach MS, Dunn C, Spano J, Secor PR, Tian L, Bollyky PL, Milla CE.
    J Cyst Fibros; 2024 Oct 25. PubMed ID: 39490215
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of bacteriophages in the sputum of cystic fibrosis patients.
    Saussereau E, Vachier I, Chiron R, Godbert B, Sermet I, Dufour N, Pirnay JP, De Vos D, Carrié F, Molinari N, Debarbieux L.
    Clin Microbiol Infect; 2014 Dec 25; 20(12):O983-90. PubMed ID: 24920209
    [Abstract] [Full Text] [Related]

  • 16. The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
    Law JP, Wood AJ, Friman VP.
    Microbiol Spectr; 2022 Dec 21; 10(6):e0184222. PubMed ID: 36453898
    [Abstract] [Full Text] [Related]

  • 17. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J, Abdelghany SM, Quinn DJ, Schmid D, Megaw J, Donnelly RF, Jones DS, Kissenpfennig A, Elborn JS, Gilmore BF, Taggart CC, Scott CJ.
    J Control Release; 2015 Jan 28; 198():55-61. PubMed ID: 25481442
    [Abstract] [Full Text] [Related]

  • 18. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V, Ratjen F.
    Cochrane Database Syst Rev; 2017 Oct 05; 10(10):CD009528. PubMed ID: 28981972
    [Abstract] [Full Text] [Related]

  • 19. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Smith S, Waters V, Jahnke N, Ratjen F.
    Cochrane Database Syst Rev; 2020 Jun 10; 6(6):CD009528. PubMed ID: 32520436
    [Abstract] [Full Text] [Related]

  • 20. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Barclay ML, Begg EJ, Chambers ST, Thornley PE, Pattemore PK, Grimwood K.
    J Antimicrob Chemother; 1996 Jun 10; 37(6):1155-64. PubMed ID: 8836818
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.